Analyst Summary: Biofrontera Inc. reported a record full-year 2022 financial result, with total revenues of $28.7 million, a 19% increase from 2021, driven by higher volume sales of Ameluz and an Ameluz price increase. The company plans to expand the salesforce, which is expected to grow 2023 revenues by at least 25%. Biofrontera's net loss for the full year of 2022 was $640k, compared to $37.7 million in 2021, and the company aims to be cash flow positive within approximately two years. Management has also decided to no longer provide preliminary quarterly revenue results but will continue to provide complete financial results accompanied by management conferences quarterly. The focus of Biofrontera's portfolio is on photodynamic therapy (PDT) and topical antibiotics in the treatment of dermatological conditions. The company's licensed products include treatments for actinic keratoses and impetigo.